DarioHealth (NASDAQ:DRIO – Get Free Report) and Firefly Neuroscience (NASDAQ:AIFF – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.
Valuation & Earnings
This table compares DarioHealth and Firefly Neuroscience”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DarioHealth | $22.36 million | 1.62 | -$41.71 million | ($6.13) | -0.60 |
| Firefly Neuroscience | $1.80 million | 9.28 | -$19.88 million | ($0.59) | -1.80 |
Firefly Neuroscience has lower revenue, but higher earnings than DarioHealth. Firefly Neuroscience is trading at a lower price-to-earnings ratio than DarioHealth, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 5.0% of Firefly Neuroscience shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 6.9% of Firefly Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares DarioHealth and Firefly Neuroscience’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DarioHealth | -169.87% | -54.81% | -33.36% |
| Firefly Neuroscience | -506.23% | -90.17% | -72.05% |
Analyst Ratings
This is a summary of recent recommendations for DarioHealth and Firefly Neuroscience, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DarioHealth | 1 | 1 | 2 | 0 | 2.25 |
| Firefly Neuroscience | 1 | 0 | 0 | 0 | 1.00 |
DarioHealth presently has a consensus target price of $10.00, suggesting a potential upside of 170.27%. Given DarioHealth’s stronger consensus rating and higher probable upside, equities research analysts plainly believe DarioHealth is more favorable than Firefly Neuroscience.
Risk and Volatility
DarioHealth has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Firefly Neuroscience has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Summary
DarioHealth beats Firefly Neuroscience on 10 of the 14 factors compared between the two stocks.
About DarioHealth
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
About Firefly Neuroscience
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.
Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.
